Arch Pharma eyes $100 mln by 2010 from DSM deal
MUMBAI Dec 4 (Reuters) - India's Arch Pharma Labs expects to get at least $100 million by 2010 from the bulk drug manufacture deal it has entered with Dutch chemicals group DSM (DSMN.AS), a top official said on Tuesday.
The deal involves contract manufacture of a wide variety of drugs including treatments for central nervous system disorders and heart ailments, Ajit Kamath, Chairman of the unlisted Indian firm said.
Global drug makers are increasingly sub contracting drug manufacture to Indian firms to save cost. (Reporting by Bharghavi Nagaraju; Editing by Prem Udayabhanu )